| Trial | Name |
| 0C-05-5 | A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies. |
| 0C-07-3 | Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination with Vandetanib. |
| 0C-07-7 | A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies. |
| 0C-07-9 | A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction. |
| 0C-08-4 | A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. |
| 0C-09-3 | A Phase I, Multi-Arm, Dose Escalation Study of Brivanib Alaninate Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Solid Tumors. |
| 0C-09-4 | An Open-label Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers with EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations. |
| 0C-09-7 | A Phase I/II Study of the Combination of RDEA119 and Sorafenib in Patients with Advanced Cancer. |
| 0C-09-8 | A Phase I Open-Label, Dose-Escalation Study of Veliparib in Combination with Bi-Monthly FOLFIRI in Subjects with Advanced Solid Tumors. |
| 0C-10-1 | An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 Administered Daily in Patients with Locally Advanced or Metastatic Solid Tumors. |
| 0C-99-1 | Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine. |
| 0S-00-15 | Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer. |
| 0S-00-16 | Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer. |
| 0S-01-18 | Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with CPT-11-Based Chemotherapy. |
| 0S-03-2 | Comprehensive Tissue Repository: A Study of the Biology, Pathogenesis, Etiology, and Genetics of B-Cell and T-Cell Lymphoproliferative Disorders. |
| 0S-04-5 | Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients with Cancer. |
| 0S-04-7 | USC Tumor and Tissue Bank. |
| 0S-08-12 | A Phase II, Multi-Center, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma. |
| 0S-08-15 | Cancer Genetics Family Registry - Molecular Genetics Studies of Cancer Patients and Their Relatives. |
| 0S-08-6 | Collection of Peripheral Blood for Testing Feasibility of Dendritic Cell Culture and Transfection in Patients with Hematologic Disorders. |
| 0S-08-9 | Short-Term Starvation Prior to Standard Chemotherapy with Gemcitabine and Cisplatin: Feasibility and Impact on Toxicity. |
| 0S-09-1 | A Phase I Study of Chronically-Dosed, Single-Agent, ABT-888 in Patients with Either BRCA 1/2-Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer. |
| 0S-09-4 | A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients with Elevated Tissue Factor Bearing Microparticles. |
| 0S-09-5 | A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid, or Islet Cell Cancer. |
| 0S-09-8 | Characterization of Focal Liver Lesions with SonoVue-Enhanced Ultrasound Imaging: A Phase III, Intra-Patient Comparative Study versus Unenhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard. |
| 0S-10-1 | A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center. |
| 0S-10-2 | Prospective, Longitudinal, Multi-National Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma. |
| 0S-99-10 | Blood Collection in Patients with GI Cancer. |
| 13NHL-06-3 | A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies. |
| 13NHL-07-3 | Rituximab Plus CHOP Given Every 15 days with Sargramostim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. |
| 13NHL-09-2 | Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma. |
| 13NHL-09-3 | An Open-Label Study of Bendamustine Hydrochloride in Combination with Rituximab in the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma. |
| 13NHL-09-4 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) versus Matching Placebo after Patients have Achieved Complete Response with First-Line Rituximab Chemotherapy. |
| 16M-09-3 | An Open-Label Phase I Study of BB-10901 (IMGN901, huN901-DM1) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-postive Relapsed or Relapsed/Refractory Multiple Myeloma. |
| 18M-07-1 | Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma. |
| 1B-04-4 | An International Randomized Controlled Trial to Compare Targeted Intra-Operative Radiotherapy with Conventional Post-Operative Radiotherapy after Conservative Breast Surgery for Women with Early Stage Breast Cancer. |
| 1B-06-10 | EphB4 Expression in Human Breast Cancer. |
| 1B-06-9 | Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT. |
| 1B-08-1 | Pilot Study of Green Tea Supplement in Women with Ductal Carcinoma in Situ.
|
| 1B-08-2 | A Multi-Center Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. |
| 1B-09-11 | MammaPrint Implementation Project. |
| 1B-09-7 | A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer. |
| 1B-09-8 | A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Post-Menopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to Letrozole or Anastrozole. |
| 1B-10-6 | Soy Treatment for High-Risk Women. |
| 2N-06-8 | A Multi-Center, Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease. |
| 2N-08-6 | Development of DNA Methylation Markers for Early Detection of Lung Cancer. |
| 2N-09-1 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC). |
| 2N-09-3 | An Open-Label Phase II Multi-Center Study of the Safety and Activity (as Measured by FDG Pet Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients with Relapsed Non-Small Cell Lung Cancer. |
| 2O-08-3 | A Phase IB/II Trial of AMG 479 or AMG 102 in Combination with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer. |
| 3C-03-19 | Phase I/II Study of Celebrex and EPO906 in Patients with Metastatic Colorectal Cancer (CEPO906AUS10). |
| 3C-07-5 | A Blinded, Randomized, Phase I/II Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras Wild Type Subjects with Metastatic Colorectal Cancer. |
| 3C-09-1 | A Phase II, Open-Label, Multi-Center Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients with Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status. |
| 3C-09-2 | A Multi-Center, Open-Label, Randomized, Phase II Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease. |
| 3C-09-4 | Phase I/II Study of KRN330 plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients with Metastatic Colorectal Cancer. |
| 3C-10-1 | A Dose-Finding and Phase II Study of AZD6244 (Hyd-Sulfate) in Combination with Irinotecan in 2nd Line Patients with K-ras or B-raf Mutation-Positive Advanced or Metastatic Colorectal Cancer. |
| 3C-10-2 | A Phase I/II Study of BMS-908662 (XL281) Alone or in Combination with Cetuximab in Subjects with K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer. |
| 3G-03-4 | Phase II Study of Oxaliplatin, Xeloda, and Cetuximab as First-Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer. |
| 3G-03-5 | Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma. |
| 3G-07-1 | A Randomized Phase II Study of Patients with Locally Advanced Gastric or Gastro-Esophageal Adenocarcinoma Treated with Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine Followed By Prolonged Administration of Capecitabine. |
| 3G-07-3 | Establishing Continuous Cell Lines and Xenografts from Adult Gastrointestinal Cancers and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies. |
| 3G-07-4 | Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers. |
| 3G-09-1 | Phase IB Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas. |
| 3G-09-2 | A Randomized, Double-Blind, Placebo-Controlled Phase II Study of FOLFOX plus or minus GDC-0449 in Patients with Advanced Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma. |
| 3G-09-4 | A Phase IB Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination with 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination with 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects with Advanced or Metastatic Gastrointestinal Malignancies. |
| 3L-03-1 | A Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma. |
| 3L-08-1 | A Phase I, Open-Label, Multi-Center, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33, a Recombinant Humanized Antibody to Glypican-3 Administered Weekly in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC). |
| 3L-08-2 | A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation (STORM). |
| 3L-09-1 | GIDEON: Global Investigation of Therapeutic Decisions in Hepatocelluar Carcinoma and of its Treatment with Sorafenib |
| 3L-09-2 | A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma. |
| 3L-09-3 | A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC). |
| 3P-09-1 | Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer. |
| 3P-09-2 | A Multi-Center, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer. |
| 3P-10-1 | A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer. |
| 4A-09-1 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma. |
| 4B-08-2 | Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma. |
| 4B-09-1 | An Open-Label, Single Arm, Phase II Trial of Intravenous BI 6727 in Patients with Locally Advanced, Metastatic, or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy. |
| 4K-05-1 | Phase I/II Trial of Bortezimib and Bevacizumab (“BB-mib-mab”) in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) with Assessment of Tissue Correlates of Response. |
| 4K-09-1 | An Observational Study of Metastatic Renal Cell Carcinoma Patients Prior to Initiation of Initial Systemic Therapy. |
| 4P-05-1 | FDG PET-CT in Metastatic Prostate Cancer. |
| 4P-06-3 | A Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer. |
| 4P-06-4 | Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial. |
| 4P-07-3 | A Phase II Trial of a Combination Herbal Therapy for Men with Biochemical Recurrence of Prostate Cancer After Initial Local Therapy. |
| 4P-08-4 | Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study. |
| 4P-09-10 | AFFIRM: A Multi-National Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy. |
| 4P-09-11 | A Randomized, Double-Blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration-Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel. |
| 4P-09-14 | Molecular Characterization of Circulating Tumor Cells in Prostate Cancer Patients. |
| 4P-09-2 | A Phase I/II, Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects. |
| 4P-09-4 | Phase IB/II Evaluation of RAD001 with Docetaxel and Bevacizumab in Patients with Metastatic Androgen-Independent Prostate Cancer. |
| 4P-09-8 | LHRH and LH Receptor Expression and Polymorphisms as Prognostic and Predictive Markers in Prostate Cancer. |
| 4P-10-5 | How Well Patient Perception of Pad Use Correlates with the Actual Degree of Incontinence in Men with Post-Prostatectomy Incontinence and Factors Which Motivate Men to Seek Treatment for Incontinence. |
| 4T-03-1 | A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients with Refractory Germ Cell Carcinoma. |
| 4T-09-1 | Multi-Center Phase II Trial of ARQ 197 for Subjects with Relapsed or Refractory Germ Cell Tumors. |
| 5C-10-1 | Exploration of Novel pan-HPV Treatments to Block Development of AIDS-Associated Cancer. |
| 5GYN-07-1 | A Phase III, Multi-Center, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma. |
| 5O-08-2 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) to First-Line Chemotherapy in Patients with Optimally Debulked (<1 cm) Epithelial Ovarian Cancer. |
| 5O-09-1 | A Multi-Center, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer. |
| 6CNS-07-1 | Establishment of USC CNS and Spine Tumor Bank. |
| 6G-08-1 | A Prospective, Multi-Center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM. |
| 7H-08-2 | Assessing the Role of Differentiated and Non-Differentiated Cell Types in the Development of Head and Neck Cancers. |
| 9L-03-1 | Treatment of Newly Diagnosed Adult Acute Lymphoblastic Leukemia with Intensified Post-Remission Therapy Containing PEG-Asparaginase. |
| 9L-06-4 | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation. |
| 9L-08-3 | A Multi-Center, Open-Label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib. |
| 9L-08-4 | A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome. |
| 9L-09-7 | A Phase I, Open-Label, Multi-Center Study of MDX-1338 (BMS-936564) in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia. |
| ACRIN6678 | FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer. |
| ACRIN6682 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer. |
| AMC-048 | Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’s and Atypical Burkitt’s Lymphoma. |
| AMC-053 | Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin’s Lymphoma. |
| AMC-058 | A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials. |
| AMC-059 | A Phase I/II Trial of PTC299 in Patients with HIV-Related Kaposi's Sarcoma. |
| ctsu/ACOSOGZ1071 | A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Pre-Operative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis. |
| ctsu/Calgb80405 | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. |
| ctsu/Calgb90203 | A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. |
| ctsu/CALGB90601 | A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma. |
| ctsu/E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (=/>4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC). |
| ctsu/E2804 | The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma. |
| ctsu/E3805 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. |
| ctsu/E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. |
| ctsu/RTOG0848 | A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. |
| GOG-0214 | Phase II Double-Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND #79,610). |
| GOG-0240 | A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix. |
| RTOG-0517 | Randomized Phase III Trial to Evaluate RadioPharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer. |
| RTOG-0534 | A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy. |
| RTOG-0614 | A Randomized Phase III Double-Blind Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy. |
| RTOG-0825 | Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. |
| SWOG-9007 | Cytogenetic Studies in Leukemia Patients. |
| SWOG-S0221 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer. |
| SWOG-S0230 | Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer. |
| SWOG-S0337 | A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer. |
| SWOG-S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment. |
| SWOG-S0518 | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients. |
| SWOG-S0709 | A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics. |
| SWOG-S0711 | Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction. |
| SWOG-S0715 | Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane-Induced Neuropathy, Phase III. |
| SWOG-S0720 | Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). |
| SWOG-S0722 | A Phase II Trial of MTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM). |
| SWOG-S0800 | A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) plus Pegfilgrastim (Peg-G) as Neo-Adjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer. |
| SWOG-S0809 | A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC). |
| SWOG-S0904 | Randomized Phase II Study of Docetaxel followed by Vandetanib (ZD6474) vs. Docetaxel plus Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| SWOG-S0941 | Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma. |
| SWOG-S9910 | Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary. |
